Tersus Animal Health has researched and studied the close correlation between fat tissues and chronic low-grade inflammation associated with metabolic syndrome. This correlation is directly related to an enzyme known as SCD1 – Stearoyl-CoA desaturase 1.
In in-vitro laboratory conducted studies, when SCD1 activity is removed from lab animals, their levels of fat tissue inflammation are drastically reduced while their ability to respond to insulin sensitivity rises. Follow-up in-vitro laboratory studies have demonstrated that by adding Omega 7 to cultures of fat cells, these same benefits occurred made, possible by the suppression of SCD1 activity.
Animal studies have demonstrated significant reductions of fat-related inflammatory cytokines (signaling molecules) following administration of Omega 7. Similarly, hepatic benefits have been observed by studying the livers of Omega 7 supplemented animals demonstrating significant reductions of the count of activated inflammatory cells, a very positive effect that may help prevent fatty liver disease in animals and humans alike.
There exists impressive human clinical data demonstrating Omega 7’s method of action and ability to lower inflammation and reduce the resulting cardiovascular and life shortening and threatening risks. In a Tersus Pharmaceutical sponsored study conducted on adult humans with high level C-reactive protein (primary blood bio-marker of inflammation), supplementation with 210mg daily Omega 7 resulted in a remarkable 44% decrease of C-reactive protein.
Research and clinical trials have shown that TRIVONAL® Omega 7 has multiple beneficial effects on a majority of the metabolic, physiological and pathological components of metabolic syndrome. TRIVONAL® Omega 7 has scientifically and clinically proven to stop the inflammation that forms the direct link between metabolic syndrome and its life-shortening and life-threatening consequences.
Studies and Clinical Studies
Case Study: Dry Eye In Dogs
– Dr. Megan Barnhizer, Animal Hospital Inc., Willoughby Ohio August 2014
Palmitoleic Acid (N-7) Attenuates the Immunometabolic Disturbances Caused by a High-Fat Diet Independently of PPARa
– University of Sao Paulo, Brazil – June 2014
Infusion of Palmitoleic Acid in Obese Sheep – Clemson Animal and Veterinary Sciences, July 2013
Provinal In The Reduction of CRP – Xyrion Medical Institute, Physician Training and Speciality Clinic, May 2013
Effects of Two Dosage Levels of Provinal® (purified Palmitoleic Acid; C16:1n7; Omega 7) on Serum Lipid and C-Reactive Protein (CRP) Profiles in Humans
– Tersus Pharmaceutical Cleveland Ohio – June 2012
Regulation of Lipid Metabolism by Palmitoleate and EPA in Mice Fed a High-Fat Diet
– Arch Department of Clinical Dietetics and Human Nutrition, Josai University – July 2011
– Zhi Hong Yang, Hiroko Miyahara and Akima Hatanaka, Lipids in Health and Disease 2011
Elevated Palmitoleic Acid Levels Improve Insulin Sensitivity – Department of Physical and Analytical Chemistry, Uppsala University 2011
Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in U.S. Adults: A Cohort Study- Bringham and Women’s Hospital, Havard Medical School, and Havard School of Public Health, Boston, MA – December 2010
– Norbet Stefan MD, Nora Celebi MD, Harald Steiger, PhD, Jorgen Machann, PhD, Fritz Schick, PhD, Alexander Cegan, Phd, Et Al Diabetes Care – February 2010
Heart & Vascular Institute, Cleveland Clinic – January 2009